Navigation Links
New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
Date:9/18/2007

- PREZISTA/ritonavir data presented at ICAAC -

BRIDGEWATER, N.J., Sept. 18 /PRNewswire/ -- Results from a new ongoing, randomized, controlled, open-label Phase 3 study showed that 84 percent of treatment-naive HIV-1 infected adults taking an investigational dose of PREZISTA(TM) (darunavir) 800 mg (two 400 mg tablets) with 100 mg ritonavir once daily with TRUVADA(R)(1) (emtricitabine and tenofovir disoproxil fumarate) reached an undetectable viral load (<50 copies/mL) at week 48, compared with 78 percent of patients taking KALETRA(R)(2) (lopinavir/ritonavir) 800 mg/200 mg once daily (or 400 mg/100 mg twice daily) with TRUVADA. The mean difference in response between the treatment groups was 5.3 percent (95 percent confidence interval -0.5; 11.2).

Results from the study known as ARTEMIS were presented today at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. It is the first study to examine PREZISTA/ritonavir (PREZISTA/r) in treatment-naive adult patients with HIV.

ARTEMIS (AntiRetroviral Therapy with TMC114 examined in nave subjects) compared the efficacy and safety of PREZISTA/r with the protease inhibitor (PI) lopinavir/r in treatment-naive adult patients. In a pre-planned analysis, the study met the primary endpoint of non-inferiority (95 percent confidence interval lower limit for the difference in treatment response .12 percent or greater for HIV RNA of less than 50 copies per mL in plasma at week 48).

"This is an important study because it provides information regarding the potential use of a once daily PREZISTA regimen for the treatment of adult patients who have never taken HIV medications before," said Edwin DeJesus, MD, Medical Director of the Orlando Immunology Center and the HUG-Me Program's adult clinic at Orlando Regional Medical Center.

The use of PREZISTA/r in treatment-naive patients and the once-a-day 800 mg dose have not been approved by the FDA. The 48-we
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... , , PHILADELPHIA , Jan. 14 ... centralized services to the biopharmaceutical, medical device and related industries, ... written by ERT experts. Each paper discusses issues relevant to ... as an experienced and reliable partner in products and services ...
... , HORSHAM, Pa. , Jan. 14 ... the efficacy and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) ... today in The New England Journal of Medicine. ... doses of STELARA than with etanercept over a 12-week period. ...
Cached Medicine Technology:ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 2ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 3ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 4ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers 5STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 3STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 4STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 5STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 6STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 7STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 8STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 9
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... 2014) Doctors who treat patients with a ... can face an agonizing treatment decision. , The ... and help relieve shortness of breath. But some ... can cause potentially fatal complications following transplantation. , ... Dilling, medical director of Loyola University Medical Center,s ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... shows that high maternal viral load and co-infection with ... associated with vertical transmission of the hepatitis C virus ... is associated independently with the spontaneous clearance of HCV ... the mother or children did not increase risk of ...
... HealthDay Reporter , TUESDAY, April 26 (HealthDay News) ... such as clot-busting drugs and rapid angioplasty, has led to ... Researchers used data from a Swedish coronary care registry on ... of deadly heart attack known as STEMI between 1996 and ...
... NY, April 27, 2011Ninety percent of American families living ... afford health insurance under the Affordable Care Act, according ... and Ian Perry of the Massachusetts Institute of Technology ... health insurance exchanges established under the law will make ...
... BOSTON Bernard Chang, MD, a member of ... Center (BIDMC) and Assistant Professor of Neurology at Harvard ... 63rd Annual Meeting of the American Academy of Neurology, ... the award recognizes physicians in the early stages of ...
... regulatory protein can block human ovarian tumor growth, leading ... to treat the disease, according to Penn State College ... 21,880 new cases and 13,850 deaths occurred in 2010 ... forms of ovarian cancer and the most lethal gynecologic ...
... Alegre, Brazil- Tumor progression is usually ensured by more ... shut down by a specifically targeted drug, other mechanisms ... failure, they may also become an opportunity for researchers ... a paper recently published in the journal Oncology ...
Cached Medicine News:Health News:Severity of hepatitis C and HIV co-infection in mothers contribute to HCV transmission to child 2Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 2Health News:Evidence-Based Heart Attack Care Reduces Deaths: Study 3Health News:New study: Health reform to make health insurance affordable for nearly all families 2Health News:BIDMC neurologist Bernard Chang, M.D., receives award for epilepsy research 2Health News:Motor protein may offer promise in ovarian cancer treatment 2Health News:A potential novel drug-target for colorectal cancer treatment comes from the brain 2
Bone Curette, 180 mm...
Endocrette Endocervical Curette is a stainless-steel curette with closed blade....
Townsend is a endocervical stainless-steel curette with round tapered tip....
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
Medicine Products: